Successful autologous bone marrow transplantation in second remission of malignant histiocytosis.
This report describes an 18-year-old man with disseminated malignant histiocytosis (MH). The patient initially attained complete remission (CR1) with conventional chemotherapy and then relapsed 14 months later. In second complete remission (CR2) 2 years and 8 months after initial diagnosis, an autologous bone marrow transplantation (ABMT) was undertaken following conditioning with the BEAM regimen. Bone marrow collected in CR2 was incubated with mafosfamide at a dose adjusted to the individual sensitivity of normal CFU-GM according to our current protocol. At the time of writing, 4 years post-transplant, this patient remains disease free. This is the first report of ABMT with marrow treated in vitro by mafosfamide in MH.
Unité de greffe de moelle osseuse, Hôpital St Antoine, Paris, France.
B
B
Cazin
N C
NC
Gorin
J P
JP
Jouet
J P
JP
Laporte
P
P
Fenaux
M P
MP
Walter
A
A
Najman
B
B
Gosselin
F
F
Bauters
D000293:Adolescent; D001761:Bleomycin / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D054747:Histiocytic Sarcoma / Q000188:drug therapy / Q000601:surgery*; D006801:Humans; D008297:Male; D011241:Prednisone / Q000627:therapeutic use; D012074:Remission Induction; D014182:Transplantation, Autologous; D014750:Vincristine / Q000627:therapeutic use
D001761:Bleomycin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone